FDA gives PillCam Colon thumbs down
This article was originally published in The Gray Sheet
Executive SummaryGiven Imaging says Feb. 18 it received a "not substantially equivalent" letter from FDA denying its 510(k) application for the PillCam Colon, an ingestible capsule that images the colon. The firm would not disclose details of the letter, but said it is evaluating options to get the device to the U.S. market and is accelerating development of the Colon 2 next-generation capsule. PillCam Colon was approved in Europe in 2006. FDA has cleared PillCam SB 2, for the small bowel, and PillCam ESO 2, for the esophagus. On Feb. 20, Given reported 2007 sales of $112.8 million, a 19% increase over the prior year. The firm's guidance for sales in 2008 is $130 million-$136 million
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.